Dr. Wenner said blood tests could eventually be used first, to let those who know they are developing mild memory issues to know whether they will develop Alzheimer’s, Drs. Said Wener.
And, In the future, blood tests may be given to people without impairment, said Tanzi, perhaps with preliminary screening tools with PET scans if anxious levels of the biomarker were detected.
Dr. “Promised to detect the disease early, before we have any symptoms,” said Tanzi. Some areas would only recommend clinical use if there were effective ways to prevent or treat Alzheimer’s, Tangiel said.
Dr. Hanson said her lab was studying whether the test could predict dementia in people with no impairment or people with mild memory problems.
In the JAMA study a method called an immunosase was used to detect compounds that bind antibodies in the test. Many such donkeys are being developed. The study was specifically developed by Eli Lilly & Co., which provided materials and three employees for conducting the assays; The company was allowed to review the manuscript, but nothing was vetoed in it, the authors reported. Most of the funding for the study came from government agencies and foundations in Sweden and the United States.
At the conference of the Alzheimer’s Association, Drs. Hanson and a co-author, Drs. Kaj Blenno presented his findings, as did two other research teams working on the Tau blood test.
A test developed by a team at Washington University in St. Louis, in which Drs. Randall Bateman, dau. Suzanne Schindler and Nicholas Barthelemy, used a method called mass spectrometry, which detects whole molecules of tau or amyloid. In a study published Tuesday in the Journal of Experimental Medicine, that team found that the same form of tau in the JAMA study, p-tau 1717, is more closely correlated to amyloid buildup in the brain than another form, p-tau 181 is. Some researchers are focusing on it. An assistant professor of neurology, Drs. Schindler stated that P-tau 217 may first emerge in the Alzheimer’s disease process.